8-K: Pacira Reports Strong 2025 Revenue, EXPAREL Sales Growth

Pacira BioSciences announced preliminary unaudited total revenue of $726.4 million for full-year 2025, driven by record-high EXPAREL sales.

Summary

• Total preliminary unaudited revenue for the full-year ended December 31, 2025, was $726.4 million, compared with $701.0 million for 2024.
• Preliminary unaudited EXPAREL net product sales for Q4 2025 were $155.8 million, up from $147.7 million in Q4 2024, with 7% volume growth.
• Preliminary unaudited EXPAREL net product sales for full-year 2025 were $575.1 million, up from $549.0 million in 2024, with 6% volume growth.
• Preliminary unaudited ZILRETTA net product sales for Q4 2025 were $33.0 million, compared with $33.1 million in Q4 2024.
• Preliminary unaudited ZILRETTA net product sales for full-year 2025 were $116.6 million, compared with $118.1 million in 2024.
• Preliminary unaudited iovera net product sales for Q4 2025 were $7.0 million, up from $6.5 million in Q4 2024.
• Preliminary unaudited iovera net product sales for full-year 2025 were $24.2 million, up from $22.8 million in 2024.
• Other revenue for Q4 2025 was $1.1 million, compared with zero in Q4 2024.
• Other revenue for full-year 2025 was $10.5 million, compared with $11.1 million in 2024.
• The company repurchased 2.0 million shares of its common stock for $50.0 million during the fourth quarter of 2025.
• As of December 31, 2025, 41.1 million shares of common stock were outstanding, with $150.0 million remaining on the current share repurchase authorization, which expires December 31, 2026.
• Inducement awards were granted on January 5, 2026, to ten new employees, including stock options for an aggregate of 14,000 shares and restricted stock units for an aggregate of 22,300 shares of common stock.

Sentiment

Score: 8

Explanation: The filing reports solid revenue growth, particularly for its flagship product EXPAREL, and demonstrates shareholder value through share repurchases. Management's outlook is optimistic, highlighting strategic progress and future growth. While ZILRETTA sales slightly declined and some discounting occurred, the overall picture is positive, indicating strong operational execution and a promising trajectory.

Positives

• Achieved record-high EXPAREL sales in 2025, demonstrating strong product demand.
• EXPAREL volume growth of 7% in Q4 2025 marked the strongest fourth quarter performance in three years.
• Overall total revenue increased to $726.4 million for full-year 2025 from $701.0 million in 2024.
• Repurchased 2.0 million shares of common stock for $50.0 million in Q4 2025, indicating confidence in the company's value and returning capital to shareholders.
• Management expressed that the company is well-positioned for sustainable, long-term success, having achieved solid execution and meaningful progress on its '5x30 strategic priorities'.
• Entered 2026 with momentum, a strong foundation, and clear line of sight to further operational progress and growth.
• iovera net product sales increased both in Q4 2025 ($7.0 million vs. $6.5 million) and full-year 2025 ($24.2 million vs. $22.8 million).

Negatives

• EXPAREL volume growth was partially offset by a shift in vial mix and discounting associated with the launch of new group purchasing organization (GPO) partnerships.
• ZILRETTA net product sales slightly decreased in Q4 2025 ($33.0 million vs. $33.1 million) and for full-year 2025 ($116.6 million vs. $118.1 million).
• Other revenue slightly decreased for full-year 2025 ($10.5 million vs. $11.1 million).
• The financial information provided is preliminary, unaudited, and subject to adjustment, meaning final results could differ.

Risks

• Failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH.
• Risks associated with acquisitions, such as integration difficulties, higher costs, or failure to achieve expected benefits.
• Challenges related to manufacturing and the supply chain.
• Impact of global and United States economic conditions, including tariffs, inflation, and rising interest rates, on business, revenues, financial condition, cash flows, and results of operations.
• Uncertainty regarding the success of sales and manufacturing efforts for EXPAREL, ZILRETTA, and iovera.
• The rate and degree of market acceptance of EXPAREL, ZILRETTA, and iovera.
• Ability to accurately assess and serve the size and growth of potential markets for products.
• Risks associated with plans to expand the use of EXPAREL, ZILRETTA, and iovera to additional indications and opportunities, including the timing and success of related clinical trials for these products and other product candidates like PCRX-201.
• The commercial success of EXPAREL, ZILRETTA, and iovera.
• Timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s.
• Timing and success of European Medicines Agency Marketing Authorization Applications.
• Plans to evaluate, develop, and pursue additional product candidates utilizing the proprietary multivesicular liposome (pMVL) drug delivery technology.
• Approval of the commercialization of products in other jurisdictions.
• Outcomes of clinical trials in support of an existing or potential pMVL-based product.
• Effectiveness of commercialization and marketing capabilities.
• Ability to successfully complete capital projects.
• The outcome of any litigation.
• Recoverability of deferred tax assets.
• Assumptions associated with contingent consideration payments.
• Assumptions used for estimated future cash flows associated with determining the fair value of the company.
• Anticipated funding or benefits of the share repurchase program.

Future Outlook

Management anticipates sustainable, long-term success, driven by strong EXPAREL volume growth and strategic commercial investments. The company enters 2026 with momentum, a strong foundation, and a clear line of sight to further operational progress and growth. Pacira expects to report its complete financial results for Q4 and full-year 2025, along with financial guidance, later in the first quarter of 2026. The company also plans to expand product indications, pursue additional product candidates utilizing its pMVL drug delivery technology, and explore commercialization in other jurisdictions.

Management Comments

• "We closed 2025 having achieved another year of solid execution and meaningful progress advancing our 5x30 strategic priorities, leaving us well-positioned for sustainable, long-term success." Frank D. Lee, chief executive officer of Pacira BioSciences.
• "Strong EXPAREL volume growth in the second half of the year underscores the value of our commercial investments and positions us for significant and sustainable revenues moving forward." Frank D. Lee, chief executive officer of Pacira BioSciences.
• "We enter 2026 with momentum that provides us with a strong foundation and clear line of sight to further operational progress and an exciting chapter of growth ahead." Frank D. Lee, chief executive officer of Pacira BioSciences.

Industry Context

Pacira operates as a leader in the non-opioid pain therapy market, a sector experiencing increasing demand due to the ongoing opioid crisis and a shift towards safer, more sustainable pain management solutions. The reported growth in EXPAREL sales, a long-acting local analgesic, aligns with this broader industry trend. The company's advancement of PCRX-201, a gene therapy for osteoarthritis, positions it at the forefront of innovative, long-term pain solutions, potentially disrupting traditional treatment paradigms and addressing significant unmet medical needs in chronic pain.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders are positively impacted by the reported revenue growth, record EXPAREL sales, and the ongoing share repurchase program, which can enhance shareholder value.
• New employees benefit from inducement grants, aligning their interests with the company's long-term success.
• Customers benefit from the continued availability and innovation in non-opioid pain therapies (EXPAREL, ZILRETTA, iovera) and the advancement of pipeline products like PCRX-201.
• Creditors may view the company's improved financial performance and optimistic outlook as a positive indicator of its ability to meet financial obligations.

Next Steps

• Report complete financial results for the fourth quarter and full-year 2025 later in the first quarter of 2026.
• Provide financial guidance for the upcoming period later in the first quarter of 2026.
• Continue advancing the '5x30 strategic priorities' for sustainable, long-term success.
• Continue dosing in the Phase 2 ASCEND study for PCRX-201 for the treatment of knee osteoarthritis.
• Evaluate, develop, and pursue additional product candidates utilizing the proprietary multivesicular liposome (pMVL) drug delivery technology.
• Seek approval for the commercialization of products in other jurisdictions.

Key Dates

Recommendation

While the company demonstrates solid revenue growth, particularly with its flagship EXPAREL product, and is actively repurchasing shares, the preliminary nature of these results and slight declines in ZILRETTA sales warrant a 'hold' position. The long-term potential from the pipeline (PCRX-201) and strategic initiatives is promising, but investors should await the full financial results and detailed guidance in Q1 2026 for a more complete picture before making significant new investment decisions. The offsetting factors for EXPAREL growth (vial mix, discounting) also suggest a cautious approach.

Keywords

Pacira BioSciences, PCRX, EXPAREL, ZILRETTA, iovera, non-opioid pain therapy, pain management, bupivacaine liposome, triamcinolone acetonide, gene therapy, PCRX-201, osteoarthritis, financial results, revenue, share repurchase, Q4 2025, full-year 2025